Oncologists prescribe Idhifa 50mg Tablet for AML Treatment with specific IDH2 mutation. It primarily treats relapsed or refractory acute myeloid leukemia in adults. This target therapy based medicine contains Enasidenib salt that targets the specific IDH2 abnormal enzyme. As a result, inhibit cancer cell growth and proliferation.
What is AML?
AML stands for Acute Myeloid Leukemia that is a fast growing blood cancer where abnormal white blood cells rapidly multiply in bone marrow causing healthy blood cells suppression.
How Idhifa targets IDH2 Mutation?
This target therapy based medicine contains Enasidenib that inhibits mutated IDH2 enzymes like R140, R172 etc found in 8-12% of AML patients. It blocks the conversion of alpha Ketoglutarate to 2-Hydroxyglutarate (2-HG) that is responsible for blocking cell differentiation and promoting leukemia. As a result, 2-HG blockage inhibits cancer cell growth.
What Idhifa Does to help Your Blood Cells
This medicine especially lowers the 2-HG levels so your body can make healthy cells again. It directly doesn’t kill the cancer cells instead it helps them turn into normal cells. This reduces leukemia blasts over time.
How to Consume Idhifa 50mg Tablet?
The typical dosage of this medication is two 50mg tablets daily with or without food. Swallow the whole tablet as it is. Avoid breaking, crushing, biting or chewing of tablet as it can decrease its efficacy. Consult your doctor for personalized dosage and treatment duration. Dosage may vary based on the cancer stage and patient’s overall health status.
Benefits of Idhifa Tablet
Following are the major Benefits of this medication:
- Target Specificty
- Fewer Side Effects
- High Efficacy
- Combination Therapy
Side Effects of Idhifa Tablet
Following are the common side effects of this medication:
- Nausea
- Vomiting
- Low Appetite
- Fatigue
- Changes in Taste
- Low Blood Levels
- Mineral Imbalance
- Shortness of Breath
- Swelling
- Tumor Lysis Syndrome
- Jaundice
Consult your doctor immediately if symptoms persist for longer period of time than expected.
Management Tips for AML Patient
Following are the major management tips for AML patient:
- Use Target Therapy based Approach
- Prefer Combination Therapy for Effective Results
- Regular Monitoring
- Proper Symptoms Management
- Personalized Approach
- Maintain a Healthy Lifestyle
- Avoid Substance Abuse
- Stay Hydrated
- Seek Emotional Support if Required
Always consult your healthcare professional for personalized guidance, treatment approach as well as treatment type and duration.
Conclusion
To conclude, Enasidenib treats relapsed or refractory acute myeloid leukemia (AML) in adults with specific IDH2 mutations. It targets mutated IDH2 enzymes to inhibit cancer cell proliferation by blocking the conversion of alpha Ketoglutarate to 2-Hydroxyglutarate, thus normalizing blood cell production. Idhifa 50mg Tablet offers targeted specificity and fewer side effects. Management tips for AML patients include a personalized treatment approach, regular monitoring, and maintaining a healthy lifestyle. To get heavy discount on this medication, visit Globans Pharma. It provides deliveries in multiple countries such as Kenya, Germany, Brazil etc.
FAQs
1. Can Doctor completely cure Acute Myeloid Leukemia?
A-No, it can only be managed with effective medication on time.
2. Is Enasidenib part of Target Therapy?
A-Yes, Enasidenib is a part of target therapy that targets the specific IDH2 mutation in AML Treatment.
